News Neurotech International Limited

Equities

NTI

AU000000NTI9

Market Closed - Australian S.E. Other stock markets 02:11:02 2024-04-12 am EDT			5-day change	1st Jan Change
0.105 ^AUD	0.00%		+6.06%	+52.17%

Apr. 10	Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	MT
Feb. 26	Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation	Apr. 15	AQ
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	Apr. 09	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	Feb. 12	MT
Neurotech's ASD Drug Trials Exceed 90 Weeks	Feb. 07	MT
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	Jan. 28	MT
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	Dec. 19	MT
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	Dec. 04	MT
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	Nov. 14	MT
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 13	AQ
Butterfly Network Announces 5-Year Co-Development Agreement with Forest Neurotech for Next-generation Brain Computer Interfaces Using Ultrasound-on-Chip Technology	23-10-25	AQ
Neurotech International Completes Enrollment for Rett Syndrome Trial	23-09-26	MT
Alex Gorsky Joins Neurotech's Board as Lead Director	23-09-14	AQ
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	23-08-30	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	23-07-10	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	23-05-30	MT
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	23-05-03	MT
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	23-03-20	MT
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	23-03-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neurotech International Limited

Equities

NTI

AU000000NTI9

Summary

Filters